Department of Gynecology and Obstetrics, School of Medicine, Kashan University of Medical Sciences, Kashan, IR, Iran.
Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of Medical Sciences, Kashan, IR, Iran.
Biol Trace Elem Res. 2018 Aug;184(2):300-307. doi: 10.1007/s12011-017-1198-5. Epub 2017 Nov 10.
Magnesium and zinc are known to exert multiple beneficial effects including anti-inflammatory and antioxidant actions. To our knowledge, data on the effects of magnesium and zinc co-supplementation on biomarkers of inflammation and oxidative stress and gene expression related to inflammation in subjects of polycystic ovary syndrome (PCOS) are scarce. This study was conducted to evaluate the effects of magnesium and zinc co-supplementation on biomarkers of inflammation and oxidative stress and gene expression related to inflammation in subjects with PCOS. This randomized double-blind, placebo-controlled trial was conducted among 60 subjects with PCOS diagnosed according to the Rotterdam criteria, aged 18-40 years old. Participants were randomly assigned into two groups to take either 250 mg of magnesium oxide plus 220 mg of zinc sulfate (containing 50 mg zinc) supplements (n = 30) or placebo (n = 30) twice a day for 12 weeks. Biomarkers of inflammation and oxidative stress were assessed at baseline and at end of treatment. Gene expression related to inflammatory cytokines was assessed in peripheral blood mononuclear cells (PBMCs) of PCOS women with RT-PCR method. After the 12-week intervention, compared with the placebo, magnesium and zinc co-supplementation significantly decreased serum high-sensitivity C-reactive protein (hs-CRP) (- 1.6 ± 2.4 vs. + 0.1 ± 0.7 mg/L, P = 0.001) and protein carbonyl (PCO) (- 0.14 ± 0.28 vs. + 0.02 ± 0.07 mmol/mg protein, P = 0.002) and significantly increased plasma total antioxidant capacity (TAC) levels (+ 60.7 ± 69.4 vs. - 1.5 ± 141.5 mmol/L, P = 0.03). Results of RT-PCR demonstrated that compared with the placebo, magnesium and zinc co-supplementation downregulated gene expression of interleukin-1 (IL-1) (P = 0.007) and tumor necrosis factor alpha (TNF-α) (P = 0.03) in PBMCs of subjects with PCOS. Overall, magnesium and zinc co-supplementation, compared with the placebo, for 12 weeks among PCOS women had beneficial effects on serum hs-CRP, plasma PCO, TAC, and gene expression of IL-1 and TNF-α.
http://www.irct.ir : IRCT201706075623N121.
镁和锌已知具有多种有益作用，包括抗炎和抗氧化作用。据我们所知，关于镁和锌联合补充对多囊卵巢综合征（PCOS）患者炎症生物标志物和氧化应激及与炎症相关的基因表达的影响的数据很少。本研究旨在评估镁和锌联合补充对 PCOS 患者炎症生物标志物和氧化应激及与炎症相关的基因表达的影响。
这是一项随机、双盲、安慰剂对照试验，纳入了根据鹿特丹标准诊断为 PCOS 的 60 名年龄在 18-40 岁的女性。参与者被随机分为两组，分别服用 250mg 氧化镁加 220mg 硫酸锌（含 50mg 锌）补充剂（n=30）或安慰剂（n=30），每天两次，持续 12 周。在基线和治疗结束时评估炎症和氧化应激的生物标志物。采用 RT-PCR 法检测 PCOS 女性外周血单个核细胞（PBMCs）中与炎症细胞因子相关的基因表达。
经过 12 周的干预，与安慰剂相比，镁和锌联合补充显著降低了血清高敏 C 反应蛋白（hs-CRP）（-1.6±2.4 与+0.1±0.7mg/L，P=0.001）和蛋白羰基（PCO）（-0.14±0.28 与+0.02±0.07mmol/mg 蛋白，P=0.002），显著增加了血浆总抗氧化能力（TAC）水平（+60.7±69.4 与-1.5±141.5mmol/L，P=0.03）。RT-PCR 结果表明，与安慰剂相比，镁和锌联合补充降低了 PCOS 患者 PBMC 中白细胞介素 1（IL-1）（P=0.007）和肿瘤坏死因子-α（TNF-α）（P=0.03）的基因表达。
与安慰剂相比，在 PCOS 女性中补充 12 周的镁和锌对血清 hs-CRP、血浆 PCO、TAC 以及 IL-1 和 TNF-α 的基因表达具有有益影响。
Zotero 插件